Open AccessA c-Met Inhibitor Suppresses Osteosarcoma Progression via the ERK1/2 Pathway in Human Osteosarcoma Cells
Author(s) -
Weijie Chen,
Su Wu,
Yang Huang,
Tingting Zhang,
Hao Dong,
Zheng Xing,
Tao Chen,
Xiaokang Gong,
Gang Liu,
Xing Zhao
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s317122
Subject(s) - osteosarcoma , cancer research , medicine , apoptosis , in vivo , malignancy , metastasis , cancer , cell growth , pathology , biology , biochemistry , genetics , microbiology and biotechnology
Osteosarcoma is the most common primary malignancy of the bone among adolescents and children. Despite intensive chemotherapy and aggressive surgery, the 5-year survival rate of osteosarcoma still falls under 70%, mainly due to its tendency to metastasize and to develop drug resistance. Therefore, new treatments for osteosarcoma are urgently needed. HGF/c-Met signaling pathway, when dysregulated, is involved in the onset, progression and metastasis of various cancers, making the HGF/c-Met axis a promising therapeutic target.